CSF3 and cancer: The present study intended to investigate whether the prophylactic use of a G-CSF drug with a half dose in cancer patients with an intermediate risk combined with ≥1 patient-specific risk factors for FN would achieve satisfactory efficacy and safety effect during multiple cycles of chemotherapy.